Annual report [Section 13 and 15(d), not S-K Item 405]

STOCK-BASED COMPENSATION (Tables)

v3.25.4
STOCK-BASED COMPENSATION (Tables)
12 Months Ended
Dec. 31, 2025
Share-Based Payment Arrangement [Abstract]  
SUMMARY OF STOCK-BASED COMPENSATION EXPENSE RECOGNIZED FOR STOCK OPTION AWARDS

The Company has recorded stock-based compensation expense related to the issuance of restricted stock awards in the following line items in the accompanying consolidated statements of operations:

 

   

Year Ended

December 31,

 
    2025     2024  
             
Research and development   $ 51,953     $ 99,174  
Clinical     10,282      

10,000

 
Selling, general and administrative     609,239       880,507  
Total stock-based compensation expense   $ 671,474     $ 989,681  
SUMMARY OF OPTION ACTIVITY

The following table summarizes stock option activity under the 2014 and 2024 Plans:

 

    Number of
options
    Weighted-average
exercise price
    Weighted-average
remaining contractual
term (in years)
    Aggregate
intrinsic value
 
Outstanding at December 31, 2024     9,649     $ 207.84       4.45        
Granted                        
Exercised                        
Forfeited     (594 )     147.28              
Outstanding at December 31, 2025     9,055     $ 211.56       3.67        
                                 
Vested and exercisable at December 31, 2025     9,055     $ 211.56       3.67        
SUMMARY OF RESTRICTED STOCK AWARD

The following table summarizes restricted stock award activity under the 2014 and 2024 Plan:

 

    Number of                 As of December 31, 2025  
    restricted
stock awards
(RSA)
    Weighted-
average
grant price
    FMV on
grant date
    Vested
number
of RSA
    Unvested
number
of RSA
 
Balance at December 31, 2024     44,261     $ 56.88     $ 2,517,630       40,244       3,859  
Granted     8,598       22.37       214,003       7,195       512  
Forfeited     (1,049 )     21.30       (21,651 )            
Balance at December 31, 2025     51,810     $ 51.87     $ 2,709,982       47,439       4,371